GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
414
c/trialwatch·posted 10 months ago by u/laila_almeida

[Question] how do you actually verify SURPASS

Press Release Sourced ×8

how do you actually verify SURPASS — that is what I am asking, and I have already read the wiki twice.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.

3,513 up / 3,099 down53% upvoted22 commentsid 4evl0e17 Sep 2025

22 comments

20 in this archive, depth 5

best — the order this archive was captured in

u/rania_salinas34 points·10 months ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/hazard_ratio_halMOD19 points·10 months ago

Added the trial identifier to the title so this thread is findable in two years.

replysharereportpermalink
u/first_hundred9 points·10 months ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/niels_norgaard5 points·10 months ago·edited

SELECT was cardiovascular outcomes, not weight

replysharereportpermalink
u/week_four_wall2 points·10 months ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/laila_almeidaOP1 point·10 months ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/iman_castellanos26 points·10 months ago

FLOW was kidney outcomes and it is the one nobody quotes

replysharereportpermalink
u/rohan_steiner33 points·10 months ago

SURPASS is the diabetes programme and reports glycaemic endpoints

replysharereportpermalink
u/renal_outcomes_rnephro-curious9 points·10 months ago

the appendix is where the interesting tables live

replysharereportpermalink
u/alcohol_aversion7 points·10 months ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/hamza_zielinski26 points·10 months ago·edited

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/yara_bakken21 points·10 months ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/camila_vasquez16 points·10 months ago

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

replysharereportpermalink
u/karl_fischer_kev15 points·10 months ago

phase 2 finds a dose, phase 3 measures the effect

replysharereportpermalink
u/blunt_coldbox_notes6 points·10 months ago

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

replysharereportpermalink
u/joaquin_trevino10 points·10 months ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/sofia_ferreira12 points·10 months ago

Same. A press release is a claim about a result; the publication is the result.

replysharereportpermalink
u/laila_almeidaOP7 points·10 months ago

check who the comparator was before you compare anything

replysharereportpermalink
u/niels_norgaard8 points·10 months ago

a mean is not a promise

replysharereportpermalink
u/rohan_cardoso4 points·10 months ago

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.